Trial Information
Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724